177 related articles for article (PubMed ID: 26809751)
1. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
Saran F; Chinot OL; Henriksson R; Mason W; Wick W; Cloughesy T; Dhar S; Pozzi E; Garcia J; Nishikawa R
Neuro Oncol; 2016 Jul; 18(7):991-1001. PubMed ID: 26809751
[TBL] [Abstract][Full Text] [Related]
2. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Clarke JL; Molinaro AM; Phillips JJ; Butowski NA; Chang SM; Perry A; Costello JF; DeSilva AA; Rabbitt JE; Prados MD
Neuro Oncol; 2014 Jul; 16(7):984-90. PubMed ID: 24637230
[TBL] [Abstract][Full Text] [Related]
3. Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Hashimoto N; Tsuboi A; Kagawa N; Chiba Y; Izumoto S; Kinoshita M; Kijima N; Oka Y; Morimoto S; Nakajima H; Morita S; Sakamoto J; Nishida S; Hosen N; Oji Y; Arita N; Yoshimine T; Sugiyama H
Cancer Immunol Immunother; 2015 Jun; 64(6):707-16. PubMed ID: 25772149
[TBL] [Abstract][Full Text] [Related]
4. Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era.
Wachtel MS; Yang S
Cancer Med; 2014 Jun; 3(3):660-6. PubMed ID: 24610705
[TBL] [Abstract][Full Text] [Related]
5. Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma.
Funakoshi Y; Hata N; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Takigawa K; Mizoguchi M
Pharmaceuticals (Basel); 2020 Dec; 13(12):. PubMed ID: 33339404
[TBL] [Abstract][Full Text] [Related]
6. Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children's Oncology Group Study.
Lulla RR; Buxton A; Krailo MD; Lazow MA; Boue DR; Leach JL; Lin T; Geller JI; Kumar SS; Nikiforova MN; Chandran U; Jogal SS; Nelson MD; Onar-Thomas A; Haas-Kogan DA; Cohen KJ; Kieran MW; Gajjar A; Drissi R; Pollack IF; Fouladi M
Neurooncol Adv; 2024; 6(1):vdae035. PubMed ID: 38596718
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab-associated intestinal perforation and perioperative complications in patients receiving bevacizumab.
Yoshimoto T; Yoshikawa K; Higashijima J; Miyatani T; Tokunaga T; Nishi M; Takasu C; Kashihara H; Takehara Y; Shimada M
Ann Gastroenterol Surg; 2020 Mar; 4(2):151-155. PubMed ID: 32258980
[TBL] [Abstract][Full Text] [Related]
8. A troublesome burden, the amplification of EGFR in glioblastoma!
Lobbous M; Nabors LB
Neuro Oncol; 2020 May; 22(5):594-595. PubMed ID: 32144420
[No Abstract] [Full Text] [Related]
9. Plasma exchange as a tool for removal of bevacizumab: Highlighting application for urgent surgery.
Neth BJ; Winters JL; Sairaj RT; Gharibi Loron A; Rahman M; Hirte R; Riviere-Cazaux C; Ruff MW; Burns TC
Neurooncol Pract; 2023 Dec; 10(6):592-595. PubMed ID: 38009115
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and signaling crosstalk in glioblastoma progression and therapy resistance.
Zarzuela L; Durán RV; Tomé M
Mol Oncol; 2023 Dec; ():. PubMed ID: 38105543
[TBL] [Abstract][Full Text] [Related]
11. Preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and resectable glioblastoma.
Wilson L; Atallah A; Romero JM
J Neurooncol; 2024 Apr; ():. PubMed ID: 38619776
[No Abstract] [Full Text] [Related]
12. Correction: Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment.
Ezaki T; Tanaka T; Tamura R; Ohara K; Yamamoto Y; Takei J; Morimoto Y; Imai R; Kuranari Y; Akasaki Y; Toda M; Murayama Y; Miyake K; Sasaki H
Brain Tumor Pathol; 2024 May; ():. PubMed ID: 38713373
[No Abstract] [Full Text] [Related]
13. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
[TBL] [Abstract][Full Text] [Related]
14. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W
Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction.
Mallick S; Gandhi AK; Rath GK
Indian J Med Paediatr Oncol; 2015; 36(4):229-37. PubMed ID: 26811592
[TBL] [Abstract][Full Text] [Related]
17. Lomustine and Bevacizumab in Progressive Glioblastoma.
Wick W; Gorlia T; Bendszus M; Taphoorn M; Sahm F; Harting I; Brandes AA; Taal W; Domont J; Idbaih A; Campone M; Clement PM; Stupp R; Fabbro M; Le Rhun E; Dubois F; Weller M; von Deimling A; Golfinopoulos V; Bromberg JC; Platten M; Klein M; van den Bent MJ
N Engl J Med; 2017 Nov; 377(20):1954-1963. PubMed ID: 29141164
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bevacizumab for the treatment of glioblastoma.
Yu Z; Zhao G; Zhang Z; Li Y; Chen Y; Wang N; Zhao Z; Xie G
Exp Ther Med; 2016 Feb; 11(2):371-380. PubMed ID: 26893618
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Takeda M; Yamanaka T; Seto T; Hayashi H; Azuma K; Okada M; Sugawara S; Daga H; Hirashima T; Yonesaka K; Urata Y; Murakami H; Saito H; Kubo A; Sawa T; Miyahara E; Nogami N; Nakagawa K; Nakanishi Y; Okamoto I
Cancer; 2016 Apr; 122(7):1050-9. PubMed ID: 26828788
[TBL] [Abstract][Full Text] [Related]
20. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
